#United States #AI Technology #cancer detection #St. Paul #Astrin Biosciences

Astrin Biosciences Forms Scientific Advisory Board

In a significant move to revolutionize early cancer detection, Astrin Biosciences has officially announced the establishment of a Scientific Advisory Board. This initiative aims to push the boundaries of what’s possible in cancer diagnostics, harnessing the power of advanced proteomics and artificial intelligence (AI). With the increasing need for effective early detection strategies, this board is expected to play a crucial role in Astrin's mission to identify cancer at its earliest and most treatable stages.

The Mission and Vision

Jayant Parthasarathy, PhD, the CEO of Astrin Biosciences, articulated the company's commitment to redefining cancer detection. "Our mission is to expand what's possible in early cancer detection. At Astrin, we believe that identifying cancer at Stage 0 should become routine rather than an exception," he stated. The formation of this advisory board features some of the most esteemed names in women's health and cancer research, all driven by a shared vision for enhancing cancer diagnoses.

The Advisory Board Members

The newly formed Scientific Advisory Board comprises several renowned experts from prestigious institutions, each bringing a wealth of experience and knowledge in the field of oncology:

• - Adrian V. Lee, PhD: A Professor at the University of Pittsburgh, Lee is celebrated for his contributions to the cellular and molecular biology of breast cancer.
• - Barbara Levy, MD, FACOG, FACS, MSCP: Serving as the Chief Medical Officer at Visana Health, Levy also holds clinical professorships at George Washington University and UC San Diego Health. She is a pioneer, being the first full-time woman physician leader at the American College of Obstetricians and Gynecologists (ACOG).
• - Ben H. Park, MD, PhD: As the Director of the Vanderbilt-Ingram Cancer Center, Park is well-known for his groundbreaking work in cancer genetics and liquid biopsy development.
• - Julio Aguirre-Ghiso, PhD: Professor of Cell Biology at Montefiore Einstein Comprehensive Cancer Center and expert in early cancer spread and dormancy.
• - Nilay Sethi, MD, PhD: Focused on gastrointestinal cancers, Sethi serves as a Physician-Scientist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.
• - Pooja P. Advani, MD: A Medical Oncologist at the Mayo Clinic, Advani specializes in early-stage breast cancer detection and treatment.
• - Thomas Gilbert, MD: Chief Clinical Officer at RAYUS Radiology, Gilbert is a leading figure in diagnostics and interventional radiology.
• - William G. Morice II, MD, PhD: As the President and CEO of Mayo Clinic Laboratories, Morice is instrumental in advancing laboratory practices and innovations.

Recent Developments

The formation of this advisory board follows the recent launch of Astrin's Certitude™ Breast, marking a milestone as the first non-imaging screening test for breast cancer which can detect the disease as early as Stage 0. This innovation represents a paradigm shift in how breast cancer is diagnosed, emphasizing the need for earlier interventions that can significantly improve patient outcomes.

The Future of Cancer Detection

The integration of artificial intelligence and deep proteomics is at the forefront of Astrin's approach. The company leverages a non-invasive method that analyzes signals from over 9,000 proteins. This advanced testing is designed to uncover the earliest molecular indicators of cancer that traditional blood tests often overlook. As the Scientific Advisory Board begins its work, there is a sense of optimism about the potential breakthroughs in cancer detection and treatment.

Astrin Biosciences is on a mission to reshape the landscape of cancer diagnostics through innovative technology, guided by the expertise of its newly formed advisory board. As they set the foundation for exciting developments ahead, the commitment to improving early cancer detection and care continues to drive the company's efforts.

For more information about Astrin Biosciences and their revolutionary approach to cancer detection, please visit astrinbio.com.